Vanda Pharmaceuticals Inc.
Genetic markers for enhancing efficacy of antipsychotic treatment with iloperidone

Abstract:

The present invention relates to the selection of patients with enhanced antipsychotic treatment efficacy with iloperidone based on a patient's genotype at one or more single nucleotide polymorphism (SNP) loci and to treatment of such patients based upon the identification of their genetic information.